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Abstract
Background and purpose: Intraprostatic ﬁducial markers (FM) improve the accuracy of
radiotherapy (RT) delivery. Here we assess geometric integrity and contouring consistency
using a T2*‐weighted (T2*W) sequence alone, which allows visualization of the FM.
Material and methods: Ten patients scanned within the Prostate Advances in Com-
parative Evidence (PACE) trial (NCT01584258) had prostate images acquired with
computed tomography (CT) and Magnetic Resonance (MR) Imaging: T2‐weighted
(T2W) and T2*W sequences. The prostate was contoured independently on each
imaging dataset by three clinicians. Interobserver variability was assessed using com-
parison indices with Monaco ADMIRE (research version 2.0, Elekta AB) and exam-
ined for statistical differences between imaging sets. CT and MR images of two test
objects were acquired to assess geometric distortion and accuracy of marker posi-
tioning. The ﬁrst was a linear test object comprising straight tubes in three orthogo-
nal directions, the second was a smaller test object with markers suspended in gel.
Results: Interobserver variability for prostate contouring was lower for both T2W
and T2*W compared to CT, this was statistically signiﬁcant when comparing CT and
T2*W images. All markers are visible in T2*W images with 29/30 correctly identi-
ﬁed, only 3/30 are visible in T2W images. Assessment of geometric distortion
revealed in‐plane displacements were under 0.375 mm in MRI, and through plane
displacements could not be detected. The signal loss in the MR images is symmetric
in relation to the true marker position shown in CT images.
Conclusion: Prostate T2*W images are geometrically accurate, and yield consistent
prostate contours. This single sequence can be used to identify FM and for prostate
delineation in a mixed MR‐CT workﬂow.
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1 | INTRODUCTION
Accurate co‐registration of magnetic resonance (MR) and com-
puted tomography (CT) images is essential in radiotherapy (RT)
planning using both modalities. MR‐CT fusion combines the supe-
rior soft tissue contrast of MR images and the electron density
from CT images, which is currently required for planning.1 How-
ever, CT and MR examinations take place at different times and
over different timescales; the acquisition of detailed MR images
covering the tumor volume may require a few minutes, while CT
is considerably faster. Physiological motion may thus affect MR
and CT images differently, and this is detrimental to the accuracy
of MR‐CT fusion. In addition, inter‐ and intra‐fraction motion may
be signiﬁcant at the time of RT delivery, introducing further
errors.2,3 In order to mitigate this, ﬁducial markers can be placed
into relatively mobile tumors (or their vicinity), enabling more pre-
cise image co‐registration to be performed for MR‐CT fusion dur-
ing the planning process4 and position veriﬁcation prior to each
fraction.5,6 A more accurate MR‐CT co‐registration will enable bet-
ter targeting, therefore markers must be visible, both in MR and
CT.
Metallic markers appear bright on CT, often surrounded by
reconstruction and beam hardening artifacts,7,8 but do not yield MR
signals and are seen as dark “void” areas on MR. Their susceptibility
cause variations in the magnetic ﬁeld in their vicinity, and they are
often better visualized in T2*‐weighted (T2*W) images where the
signal loss around the markers is emphasized.9 The design of MR
protocols for RT planning thus requires not only geometric accuracy
but also that the markers are clearly visible and the image contrast
provides conﬁdence in target outlining. Uncertainties and variation in
target delineation during RT planning adds a further systematic error.
MRI allows a reduction in interobserver variability for prostate con-
tours compared to CT,10 however, this is dependent on the
sequence used.11 Previously it has not been possible to provide one
single sequence that enables both visualization of the markers and
target outlining, and this adds a degree of complexity to the RT plan-
ning workﬂow.
This work investigates a sequence suitable for MR‐CT fusion for
prostate RT using ﬁducial markers; in our institution, a set of three
gold seeds is implanted in each patient. The MR protocol we imple-
mented consists of two sequences; one standard T2‐weighted (T2W)
sequence used in diagnostic prostate scans, thus optimized for visu-
alization of intra‐prostatic structures, and a second T2*W sequence
optimized for marker visualization using the combination of several
gradient‐echoes with different echo‐times (TE) which follow each
excitation. The second sequence maximizes visualization of the
markers for RT planning fusion.
Studies so far for similar sequences have focused on accuracy of
ﬁducial detection.12–17 In this article we examine the T2*W
sequence and investigate whether it is possible to use this sequence
alone in prostate studies, considering geometric integrity, the ability
to locate marker positions and the ability to provide enough contrast
for prostate volume outlining.
2 | MATERIALS AND METHODS
2.A | Patient population
Patients were scanned at 1.5 T (Siemens Aera, Erlangen, Germany)
as part of the Prostate Advances in Comparative Evidence (PACE)
trial (NCT01584258). PACE A randomizes patients between prosta-
tectomy and stereotactic body radiotherapy (SBRT) to a dose of
36.25 Gy in ﬁve fractions, and PACE B randomizes patients between
SBRT and conventionally fractionated RT, either 62 Gy in 20 frac-
tions or 78 Gy in 39 fractions. Patients do not receive androgen
deprivation therapy. A minimum of 1 week prior to planning imaging,
three 1.0 × 3.0 mm knurled gold markers are inserted into the pros-
tate. Fiducial positions are used to fuse the CT and MR scans and
for position veriﬁcation prior to each treatment.
2.B | Planning CT acquisition
At the Royal Marsden Hospital, all patients receiving RT in PACE
have a RT planning CT followed, on the same day, by a planning
MRI scan. Patients are scanned with bladder ﬁlling and rectal prepa-
ration as per institutional guidelines and no intravenous contrast is
used. Patients receive 2 days of rectal preparation with enemas prior
to planning, and an enema just before their planning CT scan. The
CT scan incorporates axial slices of 1.5 mm from mid lumbar spine
to below the obturator foramen.
2.C | Planning MRI acquisition
Prostate MRI examinations were undertaken with two two‐dimen-
sional (2D) sequences, covering the prostate volume in 28 adjacent
slices (2.5 mm thickness). The ﬁrst one is a standard T2W pulse
sequence used in diagnostic MRI of the prostate. This sequence is
based on fast spin‐echoes and allows visualization of internal struc-
ture of the prostate (central and peripheral zone and urethra). The
second sequence is applied to the same locations, but it is gradient‐
echo‐based and maximizes the signal loss surrounding the markers.
For that purpose, we employed a sequence, which combines several
gradient‐echo signals, with a range of echo‐times (TE), into one sin-
gle image. This strategy maintains the signal‐to‐noise ratio in T2*W
acquisitions and has been used for other clinical applications.18,19
Both sequences cover the same volume, centered on the prostate
and including at least part of the pelvic bones. Both sequences use
the same shimming volume to optimize the magnetic ﬁeld homo-
geneity and the manufacturer's own distortion correction software
(in 2D). Parameters of both sequences are provided in Table 1.
2.D | Geometric integrity
The ﬁeld inhomogeneity of the main magnet and the non‐unifor-
mity of gradient ﬁelds are known to progressively affect the MR
images as the distance from the magnet isocenter increases.
Although it is unlikely that the local MR‐CT co‐registration could
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be affected by geometric distortion at the prostate location, close
to the isocenter, we characterized the hardware‐related geometric
distortion over the imaging volume. For that purpose we acquired
CT and MR images of a previously described test object consisting
of straight tubes in three orthogonal directions, known as “Linear
Test Object.”20 Images were co‐registered and evaluated using the
three‐dimensional (3D) slicer software package (www.slicer.org).21
Displacements of test object structures between CT and MR
images can be easily detected if they reach half of the voxel size
— a level of accuracy that is sufﬁcient for the purposes of this
study.
In addition a second test object was built by suspending the
markers in a gel volume comparable with a prostate (porcine gel,
Sigma‐Aldricht, St. Louis, MI, 100 g/L, approximately 90 cm3) to ver-
ify whether the position of the markers is correctly depicted in the
MR images with the sequences used. This step is necessary because
the markers themselves disturb the ﬁeld inhomogeneity, and the
associated signal loss is not necessarily symmetric in relation to the
true marker position.22 Therefore, in marker‐based registration, it is
important to verify that systematic errors are not being introduced.
The markers were orientated approximately in the superior/in-
ferior direction, which most closely resembles their orientation in
clinical examinations (Fig. 1). However, the object was rotated by
90° for a second MR acquisition, to evaluate how the
susceptibility‐related signal loss depends on orientation, and also
scanned at different orientations. In order to verify whether
systematic errors were introduced, two CT‐MR registrations were
produced. The ﬁrst gold standard registration employs the outline
of the test object volume, visible in MR and CT. The second
registration employs only the marker information, and registration
coordinates are compared. In addition, a capsule of cod liver oil
was placed on top of the test object to provide a standard for
displacements associated with chemical shift. The fat‐water
chemical shift is known to be 3.5 ppm (225 Hz at 1.5 T), and fat‐
water displacement was measured by using a readout gradient
reversal.23
2.E | Clinical studies
2.E.1 | Patient population
Ten patients with localized prostate cancer treated consecutively
within the PACE trial with SBRT at the Royal Marsden Hospital,
Sutton, from January 2015 to December 2016 were selected.
Each patient had three imaging datasets‐ RT planning CT, T2W
and T2*W MRI sequences as described. Examples are seen in
Fig. 2.
2.E.2 | Visibility of ﬁducials
Without reference to the CT images, T2W and T2*W images were
reviewed to assess the number of ﬁducial markers visible.
2.E.3 | Volume deﬁnition
Using Research Monaco 5.19.02 (Elekta AB, Stockholm, Sweden),
the prostate contour was delineated on each of the three
TA B L E 1 Parameters of MRI sequences for prostate RT Planning.
T2W acquisition (2D T2W FSE) T2*W acquisition (2D “medic”)
FOV readout (phase) 240 mm (100%) 240 mm (100%)
PE oversampling 60% 60%
Number of Slices 28 28
Slice thickness/gap 2.5 mm/0 2.5 mm/0
Acquisition matrix (phase) 320 (75%) 256 (75%)
TE/TR 110 ms/7210 ms 24 ms/550 ms
Averages 3 2
Orientation Transaxial Transaxial
PE direction Left/right Left/right
Reconstruction matrix 320 × 320 512 × 512
Receiver bandwidth 200 Hz/pixel
Fat‐water shift = 0.84 mm
230 Hz/pixel
Fat‐water shift = 0.92 mm
Pixel size 0.75 mm × 0.75 mm 0.46875 mm × 0.46875 mm
Other Echo‐train length 25, echo spacing 9.98 ms,
echo‐trains per slice 16
Combined echoes 5, ﬂip Angle 28 degrees
Filters PrescanNormalize/DistCorrection 2D PrescanNormalize/DistCorrection 2D
Coil arrangement Spine coil & body array Spine coil & body array
Total acquisition time 2 min 46 s
Parallel imaging = 2 (GRAPPA)
6 min 4 s
Parallel imaging = 2 (GRAPPA)
FSE: fast spin echo; FOV: ﬁeld of view; TE: echo time; TR: relaxation time; GRAPPA: GeneRalized Autocalibrating Partial Parallel Acquisition.
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sequences for all ten patients by three clinicians from the same
institution (AP, AT, and DB) experienced with prostate contouring
on both CT and MRI. The clinicians were instructed to contour
the prostate alone; that is, excluding the seminal vesicles (SV).
Contouring was completed on each dataset independently, with-
out reference to the other two types of imaging. The three
sequences for each patient were contoured during three separate
sessions, with at least 2 weeks between each session to minimize
recall bias.
2.E.4 | Contour variability
Inter‐observer variability, as a measure of consistency, was
assessed for each sequence by comparing each individual clinician
contour to a Simultaneous Truth and Performance Level
Estimation (STAPLE) contour24 formed from all three clinician
contours.
Monaco ADMIRE software version 2.0 was used to generate a
combination of contour comparison indices25,26 to analyze the
F I G . 1 . (a) Gel test object containing
gold seeds (schematic diagram and photo
showing gold seeds suspended in gel), (b)
Standard test object position, gold seeds
approximately lined up with main magnetic
ﬁeld as in most clinical examinations, and
transaxial slices acquired, (c) Alternative
orientation, gold seeds at 90° with static
magnetic ﬁeld B0. Images for slices A, B,
and C are shown in Fig. 3.
F I G . 2 . The three imaging sequences used for prostate contours showing the corresponding levels for the same patient. From left to right (a)
CT imaging‐ ﬁducials seen as bright markers with surrounding artifact (b) T2*W MRI sequence‐ ﬁducials seen as dark void areas (c) T2W MRI
sequence‐ ﬁducials not visible.
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difference between clinician contours for the same imaging dataset.
Distance measurements included the Hausdorff distance (HD) and
mean distance between contours. Overlap measures included Dice
similarity co‐efﬁcient (DSC) and Cohen's Kappa. A shorter distance
between contours or higher overlap index indicates higher agree-
ment between observers. The Shapiro–Wilk test conﬁrmed non‐nor-
mality of the data using SPSS Statistics, version 23. Therefore a
separate Freidman's test was performed for all four delineation met-
rics, examining for differences across the three imaging modalities.
Where signiﬁcant, pair‐wise group comparison was undertaken using
Wilcoxon's signed rank testing with Bonferroni correction.
3 | RESULTS
3.A | Geometric integrity
Figure 3 shows Maximum Intensity Projections (MIPs) of the Linear
Test Object dataset, and a 3D view for the T2W and T2*W
sequences. All lines appear straight within the volume studied
(240 × 240 × 70 mm3). Displacements from true position were esti-
mated to be smaller than half of the voxel size (i.e., under 0.375 mm
in the Left/Right and Anterior/Posterior direction). In the Superior/
Inferior direction the slice thickness is 2.5 mm and no signiﬁcant dis-
tortion could be detected. Using the T2*W sequences several imper-
fections of the test object become apparent as areas of signal loss
associated with localized ﬁeld inhomogeneity, but all tubes still
appear straight.
Considering the test object with markers suspended in gel, the
markers are always clearly visible in T2*W images; in T2W images
the signal loss is much smaller, as expected (Fig. 4). MR and CT
images were co‐registered and displacements were shown to be
smaller than half pixel size. The signal loss in MR images was thus
shown to be symmetric in relation to the true marker position shown
in CT images. For both sequences the displacement of fat signals in
relation to water signals due to chemical shift was conﬁrmed to be
less than 1 mm, as expected.
Figure 5 shows an example of a clinical examination, with
markers in different orientations. Both test object and clinical
examinations show different levels of signal loss around the gold
seeds.
A larger area of signal loss associated with the marker in the cen-
ter of the gel test object was obtained irrespective of test object ori-
entation, and was therefore investigated; the three markers appear
identical in CT and ultrasound images and there are no visible air
bubbles in the gel preparation. In order to gain further insight, the
gel test object was rebuilt: the gold seeds were removed from the
gel and cleaned with ethanol and placed in a new batch of gel in the
same container, but in different positions. This resulted in almost
identical images, the signal loss around one particular gold seed per-
sisted being much larger than the signal loss surrounding the others,
for any orientation. Therefore, although the signal loss pattern is
expected to depend on seed orientation and position, it is also quite
possible that one particular gold seed has a different magnetic sus-
ceptibility.
F I G . 3 . T2W (top) and T2*W (bottom) images of the Linear Test Object comprising straight tubes in three orthogonal directions. The
maximum intensity projections (MIPs) show the brightest pixel along a given direction, in a three‐dimensional volume. All tubes appear straight
(3D view) and overlap in the MIPs in all three directions. Signal loss associated with susceptibility‐related ﬁeld inhomogeneity is visible in
T2*W images (arrows), as expected.
PATHMANATHAN ET AL. | 31
F I G . 4 . Gel test object images showing signal loss around marker positions, which is larger on T2*W images as expected. The signal loss is
symmetric in relation to the true position of the marker. The level of signal loss associated with the markers varies, and is much larger for the
central marker, irrespective of test object orientation. Ultrasound and CT images conﬁrm there is no air gap or any imperfection at the
markers. Image intensity differences within the gel in T2W images are due to the test object construction technique, in two layers; the second
layer is built after the bottom layer has hardened sufﬁciently to hold the weight of the seeds.
F I G . 5 . Clinical example of the variation
in signal loss. Top line‐CT (left) and T2*W
(right) imaging displaying the usual signal
loss associated with a ﬁducial marker in
the cranio‐caudal position. Bottom line‐CT
(left) and T2*W (right) imaging for the
same patient showing the altered signal
loss seen with the inferior ﬁducial marker
which in this case is angled more in the
transverse plane.
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3.B | Clinical studies
3.B.1 | Visibility of ﬁducials
Review of only the T2W imaging of all patients revealed three out
of 30 ﬁducials were correctly identiﬁed. Fig. 6(a) shows an example
of the ﬁducial appearance on T2W MRI. On T2*W imaging, all 30
ﬁducial markers were visible. However, only 29 out of 30 markers
were correctly identiﬁed due to the presence of calciﬁcations creat-
ing a similar signal loss. Such calciﬁcations were variable in number
and size but were seen in eight out of the ten patients, an example
is seen in Fig. 6(b).
3.B.2 | Contour variability
Image review shows that the prostate has a high contrast appear-
ance in relation to the surrounding tissues in T2*W images, and
internal structures are not demonstrated as clearly as in T2W
sequences. Summary of the comparison metrics for all ten patients
for each imaging modality is seen in Table 2.
There is good agreement between the three observers for all
imaging modalities. Distance measurements between contours were
greater and overlap indices lower for CT compared to both MR
sequences, indicating a poorer interobserver variability for CT imag-
ing compared to MRI. This was statistically signiﬁcant when compar-
ing CT with T2*W, as indicated in Table 2.
4 | DISCUSSION
Test object images demonstrated that prostate MR images are not
signiﬁcantly distorted, and that the T2*W sequence produces a sig-
nal void that is symmetric in relation to the true marker position.
This indicates that the signal loss is sufﬁciently large to obscure the
volume immediately adjacent to the seeds where signiﬁcant image
distortion could otherwise be detected.15 Detected differences in
the size of the signal void associated with markers are expected to
relate to the marker orientation in relation to the static magnetic
ﬁeld and transaxial image plane,22,27 but small variations in the
(a)
(b)
F I G . 6 . (a) Corresponding CT (left) and
T2W (right) images for a patient showing
the appearance of a ﬁducial marker on
standard T2W imaging, as indicated by the
arrow. The second ﬁducial marker visible
on CT imaging could not be identiﬁed on
T2W images here. (b) Corresponding CT
(left) and T2*W (right) images for a
patients showing two ﬁducials with
surrounding artifact on CT images and
central calciﬁcations, all showing as signal
loss on T2*W imaging.
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magnetic susceptibility of the seeds cannot be ruled out as a con-
tributing factor.
There is a high agreement for prostate contouring on all image
sets, likely to reﬂect the high level of experience of all clinicians,
from the same institution and familiar with using MRI for contouring.
The higher agreement for contours on MRI compared to CT is con-
sistent with previous studies as a result of the improved soft tissue
contrast with MRI.28,29 Despite the visual appearance of a more
deﬁned prostate capsule on the T2*W sequence, there was no sig-
niﬁcant difference in interobserver variability when compared to
T2W imaging, which again may reﬂect the users’ experience with
MR sequences. For this group of observers, the T2*W sequence is
similar to standard T2W imaging, but with the added beneﬁt of ﬁdu-
cial identiﬁcation.
The more recent development of MR‐guided RT allows the use
of continuous MRI during treatment for motion monitoring and gat-
ing.30 Ultimately the aim would be for an MR‐only workﬂow31 with-
out the need for markers, using soft tissue visualization alone. In this
context the T2*W sequence may be advantageous in comparison to
the standard diagnostic T2W sequence as the prostate has a high
intensity appearance and fewer internal structures are clearly
depicted. The performance of automated contouring software based
on machine learning and artiﬁcial intelligence techniques should
therefore be investigated for the T2*W sequence. However, at pre-
sent, MR‐guided delivery mostly relies on a mixed MR‐CT workﬂow
with ﬁducials allowing more accurate fusion of images4 and further
used for position veriﬁcation prior to treatment.
There have been a number of studies investigating dedicated
MRI sequences for ﬁducial detection.12–17 Both balanced steady‐
state free precession sequences13 and sequences based on spoiled
gradient‐echoes have been employed in 2D12–15 and 3D16,17 acquisi-
tions, relying on T2*‐related signal loss to create a detectable signal
void in the vicinity of the ﬁducials. The averaging of consecutive
echoes in multi‐echo recalled sequences, such as the one used here
is an attractive mechanism to increase the signal‐to‐noise ratio. Pre-
vious investigations of pulse sequences of this type focused on seed
depiction capabilities; Shieda et al.12 report superior image sharp-
ness, but did not perform contouring studies. We demonstrated a
successful combination of prostate contouring and correct seed
localization with one single sequence. Furthermore, we demon-
strated the absence of geometric distortions which could lead to sys-
tematic registration errors. We believe this is a valuable advance
toward MR‐only prostate RT planning.
The accuracy of ﬁducial detection is paramount and can be
either manual12 or automatic.13–17 However, ultimately, this must be
performed automatically, especially if intrafractional imaging is to be
used. Different methods have been described for automatic algo-
rithms including feature extraction13,15 and template matching.14,16,17
The ﬁducial detection is dependent on the signal loss, which varies
with factors including seed orientation and TE.22,27 We demon-
strated that calciﬁcations in prostate are a common source of signal
voids in T2*W images, and they have been shown to mimic ﬁducial
voids.32 Although Gustafsson et al.15 proposed to detect ﬁducials
automatically by considering images at different TEs and the pro-
gressive increase in signal loss in multiple‐echo pulse sequences, it is
unclear whether calciﬁcations will be a signiﬁcant confounding fac-
tor. Further investigation is required to determine whether false pos-
itive detection as a result of calciﬁcations is a signiﬁcant issue and
whether calciﬁcations can contribute towards MR‐CT co‐registra-
tion.32 The full potential of artiﬁcial intelligence techniques in ﬁducial
detection has not yet been realized.33
With progressively more targeted treatment delivery, the accu-
racy of delineation becomes even more essential.34 For the prostate,
this requires adequate tissue contrast of the capsule to improve con-
ﬁdence in contouring and reduce inter‐observer variability. With the
development of prostate motion monitoring in MR‐guided RT, the
prostate contour can be used for gated treatment.35 This requires
easy and accurate identiﬁcation of the target either visually or using
automated algorithms. The latter may either rely on registration of
images and propagation of contours or de novo auto‐delineation of
the prostate on new images.36–38 The sequence described here
would therefore be an attractive solution for detailing seeds and the
prostate capsule. Further work of signiﬁcance to MR‐guided RT, will
be assessment of prostate contouring by treatment radiographers39
and auto‐contouring software on the sequences used here.
5 | CONCLUSION
We have described here a single T2*W MR sequence suitable for
ﬁducial depiction and prostate contouring. These MR images were
demonstrated to be geometrically accurate, the MR signal loss sur-
rounding the ﬁducial was shown to be symmetric in relation to the
true marker position shown in CT and all markers are visible. Pros-
tate contours on MR are more consistent than CT‐based contours
with good agreement between prostate RT clinicians. We expect
TA B L E 2 Summary of the median comparison metrics for three observers contouring all ten patients for each imaging type (with interquartile
range in brackets). * Denotes a statistically signiﬁcant difference when compared to T2*W using a signiﬁcance level of P = 0.0167 (Bonferroni
correction).
Imaging modality Hausdorff distance (mm) Mean distance (mm) Cohen's kappa Dice similarity co‐efﬁcient
CT 5.01* (4.68–5.71) 0.77* (0.69–0.86) 0.92* (0.89–0.93) 0.95* (0.94–0.96)
T2W 4.09 (3.57–4.89) 0.53 (0.48–0.61) 0.94 (0.93–0.96) 0.97 (0.96–0.97)
T2*W 3.61 (3.16–3.73) 0.45 (0.43–0.48) 0.95 (0.94–0.96) 0.97 (0.96–0.97)
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T2*W sequences to be useful for a mixed MR‐CT workﬂow and fur-
thermore for MR‐guided RT.
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